BTNX
BTNX Inc. is a biotechnology company and a world leader in rapid, point-of-care diagnostics. They focus on innovation, research, development, and manufacturing of advanced in-vitro diagnostic tests for laboratories, clinics, hospitals, and physicians’ offices. The company also develops information technology systems to manage point-of-care diagnostic test results, with a strong emphasis on quality, regulatory compliance, and global distribution. BTNX offers a wide range of drug testing and harm reduction products, including rapid test strips for fentanyl, benzodiazepines, xylazine, nitazene, medetomidine, and other substances, as well as drug checking kits and solutions for harm reduction and public health initiatives.
Industries
Nr. of Employees
medium (51-250)
Products
Xylazine lateral flow test strip (liquid/powder)
Dipstick lateral flow immunoassay for qualitative presumptive detection of xylazine in liquids and powders with a reported cut-off sensitivity of 1000 ng/mL; kit formats include strips, interpretation card and, for multi-test kits, buffer tubes and swabs. Intended for forensic/presumptive use (not an IVD).
Medetomidine lateral flow test strip (liquid/powder)
Dipstick lateral flow immunoassay for qualitative presumptive detection of medetomidine in liquids and powders with a reported cut-off sensitivity of 1000 ng/mL; supplied in high-count kits with interpretation card and instructions. Forensic/presumptive use only.
Benzodiazepine lateral flow test strip (liquid/powder)
Rapid visual lateral flow immunoassay for qualitative presumptive detection of benzodiazepines in liquids or powders with a stated cut-off concentration of 300 ng/mL; provided with interpretation resources and intended for forensic/presumptive screening.
Nitazene lateral flow test strip (liquid/powder)
Lateral flow immunoassay strip for qualitative presumptive detection of nitazene-class synthetic opioids in liquids and powders with a reported sensitivity around 2000 ng/mL; kits include test strips, microscoops and interpretation card for standardized sampling. Forensic/presumptive use only.
Fentanyl lateral flow test strip (liquid/powder)
Dipstick lateral flow immunoassay for qualitative presumptive detection of fentanyl and select analogues in liquids and powders with low reported cut-off sensitivities; intended for forensic or harm-reduction screening (not a clinical IVD).
Urinalysis reagent strips and automated urine analyzers
Reagent strip formats covering multiple parameters and reflectance-photometry urine analyzers with barcode and result storage/printing options for routine urinalysis in point-of-care and laboratory settings.
Xylazine lateral flow test strip (liquid/powder)
Dipstick lateral flow immunoassay for qualitative presumptive detection of xylazine in liquids and powders with a reported cut-off sensitivity of 1000 ng/mL; kit formats include strips, interpretation card and, for multi-test kits, buffer tubes and swabs. Intended for forensic/presumptive use (not an IVD).
Medetomidine lateral flow test strip (liquid/powder)
Dipstick lateral flow immunoassay for qualitative presumptive detection of medetomidine in liquids and powders with a reported cut-off sensitivity of 1000 ng/mL; supplied in high-count kits with interpretation card and instructions. Forensic/presumptive use only.
Benzodiazepine lateral flow test strip (liquid/powder)
Rapid visual lateral flow immunoassay for qualitative presumptive detection of benzodiazepines in liquids or powders with a stated cut-off concentration of 300 ng/mL; provided with interpretation resources and intended for forensic/presumptive screening.
Nitazene lateral flow test strip (liquid/powder)
Lateral flow immunoassay strip for qualitative presumptive detection of nitazene-class synthetic opioids in liquids and powders with a reported sensitivity around 2000 ng/mL; kits include test strips, microscoops and interpretation card for standardized sampling. Forensic/presumptive use only.
Fentanyl lateral flow test strip (liquid/powder)
Dipstick lateral flow immunoassay for qualitative presumptive detection of fentanyl and select analogues in liquids and powders with low reported cut-off sensitivities; intended for forensic or harm-reduction screening (not a clinical IVD).
Urinalysis reagent strips and automated urine analyzers
Reagent strip formats covering multiple parameters and reflectance-photometry urine analyzers with barcode and result storage/printing options for routine urinalysis in point-of-care and laboratory settings.
Services
Cloud-connected mobile application for capture, machine-assisted interpretation, documentation and upload of rapid-test images to a central database to support point-of-care workflows.
Remote web-based proctoring and supervised verification workflows to support diagnostic testing programs and supervised-use requirements.
On-site and remote deployment resources including multilingual instructions, training materials, onboarding documentation and technical support for deployment of rapid diagnostic kits.
Cloud-connected mobile application for capture, machine-assisted interpretation, documentation and upload of rapid-test images to a central database to support point-of-care workflows.
Remote web-based proctoring and supervised verification workflows to support diagnostic testing programs and supervised-use requirements.
On-site and remote deployment resources including multilingual instructions, training materials, onboarding documentation and technical support for deployment of rapid diagnostic kits.
Expertise Areas
- Point-of-care diagnostic test development
- Lateral flow immunoassays for liquid and powder screening
- Microfluidic disk-panel assay development
- Reagent-strip readers and reflectance photometry
Key Technologies
- Lateral flow immunoassay
- Microfluidic disk-panel testing
- Reflectance photometry readers
- Colorimetric and immunoassay reagent chemistry
News & Updates
BTNX Inc. was founded in 2000 and has grown into a trusted leader in rapid point-of-care diagnostics, with a strong presence in over 135 countries. The company has achieved numerous milestones, including the development of the Rapid Response brand, the introduction of POCDA hardware, and supplying nearly 400 million COVID-19 tests to the Canadian government.
BTNX introduced the next generation of fentanyl test strips (2.0), which feature enhanced specificity, improved sensitivity, and include a microscoop for better testing accuracy. The new strips do not cross-react with common substances like diphenhydramine, MDMA, and methadone.
ISO 13485:2016 Certification
BTNX Inc. products are manufactured in a facility certified in conformity with ISO 13485:2016, ensuring high quality standards.
Global Presence in Over 135 Countries
BTNX Inc. has a strong international presence, distributing diagnostic solutions worldwide.
Largest Supplier of COVID-19 Tests in Canada
During the pandemic, BTNX supplied nearly 400 million COVID-19 tests to the Canadian government.
BTNX Inc. was founded in 2000 and has grown into a trusted leader in rapid point-of-care diagnostics, with a strong presence in over 135 countries. The company has achieved numerous milestones, including the development of the Rapid Response brand, the introduction of POCDA hardware, and supplying nearly 400 million COVID-19 tests to the Canadian government.
BTNX introduced the next generation of fentanyl test strips (2.0), which feature enhanced specificity, improved sensitivity, and include a microscoop for better testing accuracy. The new strips do not cross-react with common substances like diphenhydramine, MDMA, and methadone.
ISO 13485:2016 Certification
BTNX Inc. products are manufactured in a facility certified in conformity with ISO 13485:2016, ensuring high quality standards.
Global Presence in Over 135 Countries
BTNX Inc. has a strong international presence, distributing diagnostic solutions worldwide.
Largest Supplier of COVID-19 Tests in Canada
During the pandemic, BTNX supplied nearly 400 million COVID-19 tests to the Canadian government.